Coagulation parameters in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis during and after dose reduction of biologicals
Recruiting
- Conditions
- auto-inflammatory joint diseasesRheumatism1006447710023213
- Registration Number
- NL-OMON43241
- Lead Sponsor
- Jan van Breemen Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
Diagnosis RA, AS or PsA
Use of biologicals
Reducing biological due to low disease activity (to be determined by the treating rheumatologist)
Exclusion Criteria
Insufficient understanding of the Dutch language to be able to sign informed consent
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Additional blood samples will be taken during three consecutive visits to the<br /><br>'biopoli'. These will be stored at a temperature of -80 ° C. The following<br /><br>biomarkers of coagulation activation will be determined:<br /><br>F1 + 2, prothrombin fragments1 and 2<br /><br>TAT, thrombin-antithrombin complexes<br /><br>PAP, plasmin-a2-antiplasmin inhibitor complex<br /><br>TGA, trombin generation analysis</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable.</p><br>